source
- Servier’s $1.5 billion muscular dystrophy drug sevasemten fails pivotal trialServier announced that its experimental muscular dystrophy therapy sevasemten did not meet its goals in a pivotal Phase III study. The trial, named GRAND CANYON, evaluated the drug’s ability to im…
- Neurocrine launches new safety study after another death linked to Prader-Willi drug VykatNeurocrine Biosciences announced it will start a new study to evaluate dosing and safety of its rare disease drug Vykat in patients with Prader-Willi syndrome who have complex health issues. The m…